PriceTargets.com logo

Landos Biopharma - LABP Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $20.42
  • Forecasted Upside: -10.95%
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$22.93 As of 05/23/2024 09:56 PM ET
▲ +0.13 (0.57%)
Get New Landos Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LABP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LABP

Analyst Price Target is $20.42
▼ -10.95% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Landos Biopharma in the last 3 months. The average price target is $20.42, with a high forecast of $20.42 and a low forecast of $20.42. The average price target represents a -10.95% upside from the last price of $22.93.

This chart shows the closing price for LABP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 1 investment analysts is to hold stock in Landos Biopharma. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/7/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/5/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/1/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/30/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/30/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
4/1/2024HC WainwrightReiterated RatingBuy ➝ Neutral$50.00 ➝ $20.42
1/6/2023Jefferies Financial GroupDowngradeHold ➝ Underperform
8/12/2022Leerink PartnersLower TargetMarket Perform$160.00 ➝ $30.00
8/12/2022Raymond JamesDowngradeOutperform ➝ Market Perform
4/12/2022Jefferies Financial GroupDowngradeBuy ➝ Hold
3/25/2022Raymond JamesLower TargetOutperform$240.00 ➝ $90.00
1/3/2022JPMorgan Chase & Co.Lower TargetNeutral$150.00 ➝ $70.00
11/18/2021Craig HallumLower TargetBuy$450.00 ➝ $295.00
11/16/2021Leerink PartnersDowngradeOutperform ➝ Market Perform$200.00 ➝ $160.00
11/15/2021JonestradingDowngradeBuy ➝ Hold
11/1/2021HC WainwrightReiterated RatingBuy
10/20/2021Craig HallumInitiated CoverageBuy$450.00
10/19/2021HC WainwrightInitiated CoverageBuy$500.00
10/7/2021Leerink PartnersReiterated RatingBuy
9/23/2021JonestradingInitiated CoverageBuy$390.00
7/30/2021Leerink PartnersInitiated CoverageBuy$200.00
7/30/2021Raymond JamesBoost TargetOutperform$330.00 ➝ $350.00
3/8/2021Raymond JamesReiterated RatingOutperform$330.00
3/1/2021JPMorgan Chase & Co.Initiated CoverageNeutral$170.00
3/1/2021Jefferies Financial GroupInitiated CoverageBuy$320.00
3/1/2021Raymond JamesInitiated CoverageOutperform$330.00
3/1/2021Leerink PartnersInitiated CoverageOutperform$200.00
(Data available from 10/30/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 16 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/3/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/3/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/2/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/2/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/1/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/31/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/30/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/30/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Landos Biopharma logo
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that is in Phase 2 clinical trial to treat ulcerative colitis (UC) and completed Phase 1 to treat Crohn's disease (CD). The company's preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist for the treatment of asthma and eosinophilic disorders; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and neurodegenerative disorders; and LABP-69, an oral PLXDC2 agonist for the treatment of rheumatoid arthritis, UC, and CD. The company has a license and collaboration agreement with LianBio Respiratory Limited to develop, manufacture, and commercialize omilancor and NX-13. Landos Biopharma, Inc. was incorporated in 2017 and is headquartered in Blacksburg, Virginia.
Read More

Today's Range

Now: $22.93
Low: $22.75
High: $22.94

50 Day Range

MA: $22.54
Low: $21.51
High: $22.93

52 Week Range

Now: $22.93
Low: $2.50
High: $22.94

Volume

50,800 shs

Average Volume

19,700 shs

Market Capitalization

$71.77 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Landos Biopharma?

The following Wall Street sell-side analysts have issued reports on Landos Biopharma in the last year: HC Wainwright.
View the latest analyst ratings for LABP.

What is the current price target for Landos Biopharma?

1 Wall Street analysts have set twelve-month price targets for Landos Biopharma in the last year. Their average twelve-month price target is $20.42, suggesting a possible downside of 10.9%. HC Wainwright has the highest price target set, predicting LABP will reach $20.42 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $20.42 for Landos Biopharma in the next year.
View the latest price targets for LABP.

What is the current consensus analyst rating for Landos Biopharma?

Landos Biopharma currently has 1 hold rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in LABP, but not buy more shares or sell existing shares.
View the latest ratings for LABP.

What other companies compete with Landos Biopharma?

Other companies that are similar to Landos Biopharma include Achilles Therapeutics, TherapeuticsMD, Aspira Women's Health, Sensei Biotherapeutics and Adverum Biotechnologies. Learn More about companies similar to Landos Biopharma.

How do I contact Landos Biopharma's investor relations team?

Landos Biopharma's physical mailing address is 1800 KRAFT DRIVE SUITE 216, BLACKSBURG VA, 24060. The company's listed phone number is 540-218-2232 and its investor relations email address is [email protected]. The official website for Landos Biopharma is landosbiopharma.com. Learn More about contacing Landos Biopharma investor relations.